Payment overview · 2025
General Payments
$3,531.98
110 reported records · 23 companies
Healthcare provider profile · identity verified
Ying Peng, MD, PHD
Allopathic & Osteopathic Physicians|Pediatrics|Neurodevelopmental Disabilities · LADERA RANCH, CA · NPI 1528156429
Verified facts
What the public records show
CMS Open Payments records show Ying Peng, MD, PHD received $3,531.98 in general payments during 2025 across 110 reported records.
UCB, Inc. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gamunex-C.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gamunex-C by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $982.45 | 27.8% | 21 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $326.96 | 9.3% | 10 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $232.28 | 6.6% | 6 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $193.40 | 5.5% | 15 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $192.70 | 5.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $186.72 | 5.3% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $172.19 | 4.9% | 3 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $156.21 | 4.4% | 7 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $148.70 | 4.2% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$148.37 | 4.2% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $119.77 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.26 | 3.2% | 4 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $97.84 | 2.8% | 4 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $95.27 | 2.7% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.88 | 1.9% | 4 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.50 | 1.7% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$54.74 | 1.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.62 | 1.1% | 2 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $37.73 | 1.1% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.87 | 0.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $24.74 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.52 | 0.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.26 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,520.27 | 109 |
| Education | $11.71 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $412.18 | 8 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $276.97 | 7 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $232.28 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $211.98 | 9 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $187.20 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $186.72 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $172.19 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $156.21 | 7 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $148.70 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $148.37 | 6 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $124.25 | 1 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $119.77 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $114.98 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $95.27 | 3 | 2025 |
Source payment records
|
|||||
| Quillichew ER Normalized: quillichew er |
Drug | Tris Pharma Inc | $89.39 | 7 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $86.07 | 3 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $83.23 | 7 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $73.93 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $68.88 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $65.04 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $61.50 | 3 | 2025 |
Source payment records
|
|||||
| Cotempla XR-ODT Normalized: cotempla xr odt |
Drug | Neos Therapeutics, LP | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| ZONISADE Normalized: zonisade |
Drug | Azurity Pharmaceuticals, Inc. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Briviact | Brivaracetam | 23 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 21 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,531.98 · 110 records | UCB, Inc. | AJOVY, AUSTEDO XR, Briviact, Cotempla XR-ODT, Dyanavel XR, EPIDIOLEX, Fintepla, Gamunex-C, HYQVIA, Hizentra, Jornay PM, Mavenclad, Motpoly XR, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Onyda XR, PANZYGA, QULIPTA, Qelbree, Quillichew ER, SPINRAZA, Symbravo, UBRELVY, ULTOMIRIS, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZONISADE, Zilbrysq | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Grifols USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error